Joint Formulary & PAD

Abatacept - Autoimmune complications of primary immunodeficiencies caused by CTLA-4 or LRBA genetic mutation

You are here : Home > Formulary Search > Abatacept - Autoimmune complications of primary immunodeficiencies caused by CTLA-4 or LRBA genetic mutation

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Intravenous infusion
  • Subcutaneous injection (sc)
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
NHSE
Restrictions / Comments :

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Abatacept
Indication :
Autoimmune complications of primary immunodeficiencies caused by CTLA-4 or LRBA genetic mutation
Group Name :
Keywords :
Brand Names Include :
Orencia
Important Information :

Ages 2 and over

Latest Additions Date From :
25 Aug 2026
Latest Additions Date To :
25 Sep 2026
Guidelines :
Supporting Documents :
0

Committee Recommendations (0)

  • No records returned.

Other Indications

Below are listed other indications that Abatacept is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Autoimmune complications of primary immunodeficiencies caused by CTLA-4 or LRBA genetic mutation .

  • No records returned.